| Adrian Rawcliffe |
Adrian Rawcliffe is currently the Chief Executive Officer & Director at Adaptimmune Therapeutics Plc. He is also a Director at Morphotek, Inc., an Independent Director at Wave Life Sciences Ltd., and a Director at Wave Life Sciences USA, Inc. Previously, he served as the Chief Financial Officer at Human Genome Sciences, Inc. Mr. Rawcliffe's former positions include Managing Partner at GSK Equity Investments Ltd., Senior Vice President-Finance at GSK Plc, Vice President at GlaxoSmithKline Biologicals SA, and Principal at AlgoRx Pharmaceuticals, Inc. He obtained his undergraduate degree from the University of Durham in 1993. |
| William A. Bertrand |
William A. Bertrand is currently serving as an Independent Director at Ardelyx, Inc., Chief Operating Officer at Adaptimmune Therapeutics Plc, and President & Secretary at TCR2 Therapeutics, Inc. He previously served as Secretary & Director at Santarus, Inc., Director at Inotek Pharmaceuticals Corp. and BrainCells, Inc., Director at Tech Council of Maryland, Inc., Director at Trustwave Holdings, Inc., Executive Vice President & General Counsel at MedImmune LLC, COO, Secretary & General Counsel at Salix Pharmaceuticals Ltd., Partner at Dickinson Wright PLLC, and Associate General Counsel at Pharmacia Corp. He also served as Executive Vice President & General Counsel at Infinity Pharmaceuticals, Inc. and Medimmune, Inc. Bertrand received his undergraduate degree from Wayne State University (Michigan) in 1986 and his graduate degree from the University of Wisconsin in 1989. |
| Cintia Piccina |
Cintia Piccina is currently the Chief Commercial Officer at Adaptimmune Therapeutics Plc. She started this position in 2024. Prior to her current role, she held the same position at Adaptimmune Therapeutics Plc from 2022 to 2023. Cintia also has experience as the SVP-Commercial Oncology & US General Manager at 2seventy Bio, Inc. and as the Chief Commercial Officer at AlloVir, Inc. In terms of education, Dr. Piccina holds a doctorate degree from the University of Sao Paulo and an MBA from Escola Superior de Propaganda e Marketing. |
| John Lunger |
John Lunger is currently the Chief Patient Supply Officer at Adaptimmune Therapeutics Plc. He previously worked as an Independent Director at Genocea Biosciences, Inc. and as the Head-Supply Chain & Commercial Product Supply at Merrimack Pharmaceuticals, Inc. Mr. Lunger completed his undergraduate degree at the United States Naval Academy and holds an MBA from The University of Chicago Booth School of Business. |
| Elliot Norry |
Elliot Norry is currently the Chief Medical Officer at Adaptimmune Therapeutics Plc since 2020. Prior to this, he worked as a Director at Covenant Financial, Inc. Dr. Norry completed his undergraduate degree at Columbia College (MO) and holds a doctorate degree from New York University. |
| Gavin Wood |
Gavin Wood is currently the Chief Financial Officer & Director at Adaptimmune Ltd. and the Chief Financial Officer at Adaptimmune Therapeutics Plc. Previously, he was the Chief Financial Officer & Executive Director at Abcam Plc from 2016 to 2020, the Chief Financial Officer & Director at eBioscience, Inc., the Chief Financial Officer & Executive Vice President at Affymetrix, Inc. from 2006 to 2016, and the Controller at Unipart Group of Cos. Ltd. Mr. Wood received his undergraduate degree from the University of Durham. |
| Helena Katrina Tayton-Martin |
Helena Katrina Tayton-Martin is the founder. She founded Avidex Ltd. in 2008, where she held the title of Chief Operating Officer from 2008 to 2017. She also founded Adaptimmune Ltd. in 2008 and currently holds the position of COO, Director & Chief Business Officer. In 2022, she cos-founded Adaptimmune Therapeutics Plc and currently serves as the Chief Business & Strategy Officer. Dr. Tayton-Martin's current job is President & Secretary at Adaptimmune LLC. Her former positions include Independent Director at Trillium Therapeutics ULC from 2017 to 2021 and Principal at Medigene, Inc. She obtained a doctorate degree from the University of Bristol and an MBA from London Business School. |
| David M. Mott |
David M. Mott was the founder of MedImmune Ventures, Inc. (founded in 2002) where he served as President from 2002 to 2008. He is currently the Chairman of Mersana Therapeutics, Inc. (since 2012), Ardelyx, Inc. (since 2009), Complexa, Inc., Cydan LLC, Adaptimmune Therapeutics Plc (since 2014), Novavax, Inc. (since 2020), and serves as a Director at Biotechnology Innovation Organization, NEA 14 GP Ltd., and XTuit Pharmaceuticals, Inc. Mr. Mott's former positions include Vice Chairman, President & Chief Executive Officer at MedImmune LLC and MedImmune Ltd. (1992-2008), Chairman of Conceptis Technologies, Inc. and Zyngenia, Inc., Chairman-Supervisory Board at Prosensa Holding NV (2012-2015), Chairman of Epizyme, Inc. (2009-2022), and Chairman of various other companies including Sagimet Biosciences, Inc., Cydan II, Inc., Vtesse, Inc., Imara, Inc., and Clementia Pharmaceuticals, Inc. He has also served as a Director at Shire Plc, Ambit Biosciences Corp., ZP Opco, Inc., Shire Pharmaceuticals, Inc., Edimer Pharmaceuticals, Inc., Adaptimmune Ltd., Zosano Pharma Corp., Biohealth Innovation, Inc., NightstaRx Ltd., Polyneuron Pharmaceuticals AG, Nightstar Therapeutics Ltd. (2015-2019), and Tiburio Therapeutics, Inc. (2018-2020). Mr. Mott's education includes an undergraduate degree from Dartmouth College in 1986. |
| Joanna Brewer |
Joanna Brewer is currently the Chief Scientific Officer at Adaptimmune Therapeutics Plc. She started this position in 2022. Prior to her current role, she obtained graduate and doctorate degrees from the University of Cambridge. |
